Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of the Lung 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Has results × glembatumumab vedotin × Clear all
NCT02713828 2019-07-16

PrE0504

PrECOG, LLC.

Phase 1/2 Terminated
13 enrolled 12 charts

Squamous Cell Carcinoma of the Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡